About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Palatin Technologies’ Obesity Drug Receives FDA Orphan Designation; Phase 2 Results Imminent (NYSE: PTN)

NYSE: PTN)" src="https://www.abnewswire.com/upload/2025/03/1743027684.jpg" alt="Palatin Technologies' Obesity Drug Receives FDA Orphan Designation; Phase 2 Results Imminent (NYSE: PTN)" width="225" height="225">
Palatin Technologies (NYSE: PTN)* and their latest developments: Palatin’s Oral MC4R Agonist Gets FDA Orphan Drug Status; Phase 2 Results in Drug Targeting $44 Billion Obesity Market Expected Any Day According to the Company, alongside results from ulcerative colitis trial; Only Oral Option in Market Currently Dominated by Injections Uniquely Positioning Palatin

In an exciting development for the biopharma market, Palatin Technologies (NYSE: PTN)* announced that it has secured FDA orphan drug designation for PL7737, its oral melanocortin-4 receptor (MC4R) agonist, targeting obesity caused by leptin receptor deficiency. According to the company, this designation offers Palatin significant benefits, including tax credits, fee waivers, and potential seven-year market exclusivity upon approval. The company has begun toxicology studies with plans to submit an IND in Q4 2025 and expects clinical data in early 2026.

Major catalysts are approaching for Palatin. Palatin also shared that it has completed analysis of two key Phase 2 studies: the BMT-801 trial testing bremelanotide with tirzepatide for obesity, and the PL8177 trial for ulcerative colitis. Results from both are expected within days. If positive, each could be a major development for the pharma company.

PL7737, the drug that just received orphan drug designation, could revolutionize treatment for rare genetic obesity disorders. Unlike the only current FDA-approved treatment requiring daily injections, Palatin's oral formulation offers a more convenient alternative. The company is also exploring its use for hypothalamic obesity, with Phase 1 studies planned for late 2025. CEO Carl Spana called the designation "a key step in developing Palatin's MC4R receptor agonists for rare obesity conditions." The obesity therapeutics market is reportedly projected to reach $44 billion by 2030.

MC4R agonists represent a promising new class of therapeutics that may enhance existing GLP-1 treatments. Palatin's development of both injectable and oral MC4R agonists positions it to address multiple segments of the obesity market. Reportedly, A Pharma Analyst on Wall Street seems to be optimistic about Palatin’s prospects, giving the company a Buy rating with a $7.00 price target, representing a significant premium over current levels.

Click here if you'd like to receive more alerts from us

Recent Palatin Technologies News Highlights:

*DISCLAIMER: This alert is published by Wall Street Wire. Wall Street Wire does not provide financial or investment advice, and our content does not represent an offer to buy or sell securities. Wall Street Wire is a promotional content brand and its operators are not registered brokers, dealers, or investment advisers. This alert contains and is a form of paid promotional content for to Palatin Technologies and was produced as part of their paid subscription to Wall Street Wire’s distribution and promotional content services. This alert has not been reviewed or approved by Palatin Technologies prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms

Media Contact
Company Name: Wall Street Wire
Contact Person: Market Alerts Desk
Email: Send Email
Country: Germany
Website: https://newsletter.page/wallstreetalerts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  217.95
-4.08 (-1.84%)
AAPL  258.45
-4.32 (-1.64%)
AMD  230.23
-7.80 (-3.28%)
BAC  51.10
-0.42 (-0.82%)
GOOG  252.53
+1.19 (0.47%)
META  733.41
+0.14 (0.02%)
MSFT  520.54
+2.88 (0.56%)
NVDA  180.28
-0.88 (-0.49%)
ORCL  272.66
-2.49 (-0.90%)
TSLA  438.97
-3.63 (-0.82%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.